Orchestra Biomed Holdings, Inc.

As of September 11, 2025, Orchestra Biomed Holdings, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and monthly MACD, and has significantly underperformed the S&P 500 with a year-to-date return of -37.25% compared to the index's 12.22%.

As of February 9, 2023, Orchestra Biomed Holdings, Inc. is considered overvalued and risky, with poor financial metrics and a year-to-date return of -22.5%, significantly underperforming the S&P 500's gain of 2.44%.

As of June 2, 2025, the market trend is mildly bearish with mixed signals, as weekly indicators show a mildly bullish MACD while monthly indicators remain bearish, suggesting a weak bearish sentiment with potential for short-term recovery.

Orchestra Biomed Holdings, Inc. is a blank check company focused on business combinations in the biopharma and medical technology sectors. As of March 2025, it reported net sales of $1 million and a net loss of $19 million, with a market cap of $128.73 million.

As of Jun 18, Orchestra Biomed Holdings, Inc. has a market capitalization of 128.73 million, with net sales of 2.89 million and a net profit of -66.32 million over the latest four quarters. Shareholder's funds are 32.96 million, and total assets are 76.17 million as of Dec 24.